NanoVation Therapeutics

NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery).

NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.

NanoVation partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases. For additional information, please visit nanovationtx.com